A recent survey of practicing ophthalmologists conducted by Ophthalmology Times revealed a clinical landscape defined by diagnostic ambiguity, therapeutic limitation, and systemic friction. Although ...
FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...
Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...
Desk workers reported 99.2 hours of weekly screen time, with weekday exposure comprising 93% of waking hours, underscoring ...
Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...
The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).
A 1:1 randomized clinical trial compared personalized coaching plus electronic adherence monitoring against standard mailed education, with both groups continuing usual glaucoma care. Participants ...
Earlier pegcetacoplan treatment preserved twice as much retinal tissue compared to delayed treatment in patients with geographic atrophy (GA) secondary to age-related macular dege ...
Pitha and colleagues observed a general correlation between patterns of ophthalmic medication and total drug shortage reports in the US. Though ophthalmic drug shortages accounted for 15% of all ...
FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
Joseph Anaya, MD, and Ashkan Abbey, MD, discuss how retina specialists identify appropriate candidates for complement inhibitor therapy in geographic atrophy, set patient expectations, and monitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results